3XI logo

Biomind Labs DB:3XI Stock Report

Last Price

€0.22

Market Cap

€22.8m

7D

-22.2%

1Y

3,633.3%

Updated

12 Dec, 2024

Data

Company Financials

3XI Stock Overview

A biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. More details

3XI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Biomind Labs Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biomind Labs
Historical stock prices
Current Share PriceUS$0.22
52 Week HighUS$0.72
52 Week LowUS$0.0005
Beta0.028
1 Month Change-36.36%
3 Month Change-49.78%
1 Year Change3,633.33%
3 Year Change-75.65%
5 Year Changen/a
Change since IPO-81.18%

Recent News & Updates

Recent updates

Shareholder Returns

3XIDE PharmaceuticalsDE Market
7D-22.2%2.6%1.1%
1Y3,633.3%-7.8%10.3%

Return vs Industry: 3XI exceeded the German Pharmaceuticals industry which returned -7.8% over the past year.

Return vs Market: 3XI exceeded the German Market which returned 10.3% over the past year.

Price Volatility

Is 3XI's price volatile compared to industry and market?
3XI volatility
3XI Average Weekly Movement62.7%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 3XI's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3XI's weekly volatility has decreased from 2640% to 63% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a5Alejandro Antalichwww.biomindlabs.com

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder.

Biomind Labs Inc. Fundamentals Summary

How do Biomind Labs's earnings and revenue compare to its market cap?
3XI fundamental statistics
Market cap€22.79m
Earnings (TTM)-€673.36k
Revenue (TTM)n/a

0.0x

P/S Ratio

-33.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3XI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$704.80k
Earnings-US$704.80k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0091
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-58.0%

How did 3XI perform over the long term?

See historical performance and comparison